Erin Mills Town Centre Gift Cards are the perfect choice for your gift giving needs.Purchase gift cards at kiosks near the food court or centre court, at Guest Services, or click below to purchase online.PURCHASE HERE
Indigo Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC | Erin Mills Town Centre
*Product information may vary - to confirm product availability, pricing, shipping and return information please contact Indigo
Lung cancer is still a major cause of death globally, but the development of personalized, precision medicine has had a marked effect on treatment management and improved clinical outcomes, particularly for those with advanced stage non-small-cell lung cancer (NSCLC). EGFR mutations are the third most common mutation found in patients with advanced stage NSCLC. First-line treatment with a traditional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is indicated for most patients, but not for patients with EGFR exon 20 insertion mutations (ex20ins). Instead, recent approvals of an EGFR ex20ins-specific TKI (mobocertinib) and a bispecific antibody (amivantamab) targeting both EGFR and mesenchymalepithelial transition factor (MET) offer the potential for improved outcomes in this patient population. Furthermore, new approaches to treatment continue to be developed and trials for new agents with greater activity against ex20ins mutations are ongoing.
Lung cancer is still a major cause of death globally, but the development of personalized, precision medicine has had a marked effect on treatment management and improved clinical outcomes, particularly for those with advanced stage non-small-cell lung cancer (NSCLC). EGFR mutations are the third most common mutation found in patients with advanced stage NSCLC. First-line treatment with a traditional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is indicated for most patients, but not for patients with EGFR exon 20 insertion mutations (ex20ins). Instead, recent approvals of an EGFR ex20ins-specific TKI (mobocertinib) and a bispecific antibody (amivantamab) targeting both EGFR and mesenchymalepithelial transition factor (MET) offer the potential for improved outcomes in this patient population. Furthermore, new approaches to treatment continue to be developed and trials for new agents with greater activity against ex20ins mutations are ongoing.
The largest book retailer in Canada also offers toys, music, home décor, gifts and lifestyle products. What's Inside...Books, Magazines, CD’s and DVD’s, Toys and Gifts, Home Accents, Electronics, Baby’s and Children’s Section, Bath and Body, Kitchen and Bedroom, Stationary Located outside in the exterior plaza.
![Fast Facts: Thalassemia Syndromes [Chinese]](/whatsinstore/_next/image?url=https%3A%2F%2Fcdn.mall.adeptmind.ai%2Fhttps%25253A%25252F%25252Fcdn.shopify.com%25252Fs%25252Ffiles%25252F1%25252F0655%25252F8980%25252F5233%25252Ffiles%25252Fimage_7417dfb8-14dd-424a-94e6-b1cf2f347c36.jpg_medium.webp&w=3840&q=75)
